Danavorexton
As of the edition of 20 October 2026, Danavorexton is a small molecule: stopped in 2024; acts on HCRTR2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2024
- Kind
- Small molecule
- Registered trials
- 8, 1 stopped early
- Disease areas
- Nervous system; Lungs and airways; Mental health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| HCRTR2 | Orexin receptor type 2 | O43614 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 7 | 7 | 0 | 0 |
| Phase 2 | 1 | 0 | 0 | 1 |
| All trials | 8 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Takeda | Lead sponsor of trials | 2017 to now |